Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: Evidence to date by Cinti, Francesca et al.
© 2017 Cinti et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Drug Design, Development and Therapy 2017:11 2905–2919
Drug Design, Development and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
2905
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/DDDT.S114932
Spotlight on ertugliflozin and its potential in the 
treatment of type 2 diabetes: evidence to date
Francesca Cinti*
Simona Moffa*
Flavia impronta*
Chiara MA Cefalo
vinsin A Sun
Gian Pio Sorice
Teresa Mezza
Andrea Giaccari
Center for endocrine and Metabolic 
Diseases, Fondazione Policlinico 
Universitario A Gemelli, Università 
Cattolica del Sacro Cuore, Rome, italy
*These authors contributed equally 
to this work
Abstract: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the latest therapeutic strategy 
in the treatment of type 2 diabetes mellitus (T2DM). Using an insulin-independent mechanism 
(glycosuria), they reduce glucose toxicity and improve insulin sensitivity and β-cell function. The 
promising results obtained in clinical trials show that SGLT2 significantly improves glycemic 
control and provides greater cardiovascular protection, combined with a reduction in body 
weight and blood pressure (BP). This review focuses on ertugliflozin, a new, highly selective, 
and reversible SGLT2 inhibitor. Clinical trials published to date show that ertugliflozin, both 
as a monotherapy and as an add-on to oral antidiabetic agents, is safe and effective in reducing 
glycosylated hemoglobin (HbA1c), body weight, and BP in T2DM patients.
Keywords: antidiabetic drugs, glycosylated hemoglobin, glycemic control, sodium-glucose 
cotransporter 2 inhibitors, precision medicine, type 1 diabetes mellitus, type 2 diabetes mel-
litus, weight reduction
Introduction
The role of kidneys in maintaining glucose homeostasis is well known, but they have 
only recently become a therapeutic target in patients with type 2 diabetes mellitus 
(T2DM). Kidneys transfer all plasma glucose into urine within the nephron but subse-
quently completely reabsorb the filtered glucose through two types of sodium-glucose 
cotransporters (SGLTs),1 unless plasma glucose reaches a threshold of ~180 mg/dL. 
Thus, under physiological conditions, no glucose is present in urine. When the con-
centration of plasma glucose exceeds this threshold, SGLTs become saturated and 
glucose in excess is excreted through urine (glycosuria), a typical sign of diabetes.2 
Hyperglycemia increases the renal threshold for glycosuria, and the kidney itself 
contributes to the progression of hyperglycemia by increasing glucose reabsorption 
in response to an elevated threshold for glycosuria and by an increase in maximum 
glucose reabsorptive capacity.3
SGLTs belong to a large family of sodium-glucose cotransporters: the sodium/
glucose cotransport family SLC5.4 Two major SGLT isoforms have been described: 
SGLT2, which is highly expressed in the brush border of epithelial cells in S1 and 
S2 segments of proximal renal tubules, and SGLT1, expressed primarily in the small 
intestine, the S3 segment of the proximal renal tubule, and in the myocardium.5
In healthy humans, under normal physiological conditions, SGLT2 is responsible 
for 80%–90% of renal glucose reabsorption and SGLT1 for the remaining 10%–20%.6 
These proteins carry glucose through the membranes of the proximal tubule epithelial 
cell in an active process that involves sodium transportation, facilitated by the sodium 
gradient between the tubule and the cell, which supports secondary active cotransport 
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of glucose. Glucose then passively diffuses into the intercel-
lular space, mainly via the GLUT2 (glucose transporter 2), 
a member of the GLUT protein family.7
Data from animal models of diabetes and from preclinical 
human studies suggest that hyperglycemia in T2DM is asso-
ciated with a significantly increased expression of SGLT2 
and GLUT2 proteins.8 However, a recent paper published 
by Ferrannini et al reports a reduction of SGLT2 expression 
in diabetic patients with preserved renal function, raising 
the possibility that a higher expression may be limited to 
diseased kidneys.9
Despite the latter controversy, SGLT2 has become a new 
successful therapeutic target for the treatment of diabetes. 
In fact, blocking SGLT2 via selective inhibitors increases the 
excretion of glucose from the body (via inhibition of renal 
glucose reabsorption), thereby reducing hyperglycemia in 
T2DM. Glycosuria induced by SGLT2 inhibitors (SGLT2is) 
provides relief from glucose toxicity,10,11 thus improving 
β-cell insulin secretion and insulin sensitivity in peripheral 
tissues, leading to a further reduction in plasma glucose 
concentration.12 Added benefits are a significant reduction 
in blood pressure (BP)13 and body weight, even though the 
latter is lower than expected considering the constant calorie 
loss through glycosuria (200 kcal/day for a daily loss of 50 g 
of glucose).14
SGLT2is (aka gliflozins) also seem to provide important 
cardioprotective benefits, although the mechanism is, intrigu-
ingly, still unknown.15,16 Treatment with gliflozins induces 
a switch in energy source, from glucose to fat, leading to 
two main metabolic consequences: a reduction in glucose 
oxidation and an increase in free fatty acid oxidation with the 
stimulation of ketogenesis.14 The latter process has given rise 
to the “Thrifty Substrate” hypothesis proposed by Ferrannini 
et al to provide a potential explanation for the clinically 
observed cardiovascular (CV) benefits. The selection of 
b-hydroxybutyrate instead of fatty acids by the heart may 
enhance the efficiency at the mitochondrial level and may 
be responsible for the improved myocardial performance.17 
Lopaschuk and Verma, on the other hand, have proposed a 
contrasting hypothesis: gliflozins may inhibit myocardial 
ketone oxidation with a consequent reduction in Acetyl-CoA. 
This leads to a reduction of detrimental hyper-acetylation of 
mitochondrial enzymes and to increased pyruvate oxidation 
derived from glucose. These two actions might be responsible 
for an improvement in mitochondrial energy production and 
myocardial metabolism.18
Besides this controversy, two recent clinical trials 
with empagliflozin and canagliflozin (EMPAREG and 
CANVAS, respectively), involving subjects with T2DM 
and high CV risk, have shown, to a different extent, a sig-
nificant reduction in death from major adverse CV events 
(3-point MACE – Composite Endpoint of Major Adverse 
Cardiovascular Events: CV death, non-fatal myocardial 
infarction, or non-fatal stroke).15,16,19 An ongoing Phase III 
study (currently non-recruiting) will study the CV outcomes 
in T2DM participants with vascular disease following 
ertugliflozin treatment versus placebo (ClinicalTrials.gov 
NCT01986881).
Given this reduction in MACE events, SGLT2is are 
increasingly being used to treat T2DM. However, there is 
still a general consensus that metformin should be used as 
first-line therapy for T2DM, because in addition to lowering 
hepatic glucose production, it has a mild effect on peripheral 
resistance and could also be cardioprotective, especially in 
obese T2DM patients in primary prevention.20 SGLT2is 
are thus recommended as second- or third-line therapy for 
managing hyperglycemia in T2DM patients.21,22 This topic 
deserves a review of its own and therefore will not be dis-
cussed further in this article.
SGLT2is are also known to induce short- and long-term 
reduction in BP.23 As expected, considering their mechanism of 
action, SGLT2is are effective in reducing both systolic (SBP) 
and diastolic blood pressure (DBP), likely due to glucose-
driven osmotic diuresis, as shown by increases in hematocrit 
and decreases in body weight.24 Osmotic diuresis leads to the 
excretion of glucose and water, resulting in increased urinary 
output ranging from ~110 to 470 mL/day.24
As indicated by Mosley et al,25 SGLTi treatment can lead 
to hypotension and dehydration in elderly T2DM patients 
(ie, 65 years and older). It is therefore critical to train these 
patients to recognize dehydration symptoms (eg, dizziness, 
lightheadedness, and fainting) and orthostatic hypotension 
and to prevent dehydration by drinking adequate amounts 
of fluids.26
Diuresis, however, accounts only for the short-term 
BP reduction induced by SGLT2is. Previous studies have 
observed that urine volume returns to pretreatment levels 
after ~12 weeks of treatment with SGLT2is, whereas BP 
reduction persists,27,28 implying that diuresis is not the only 
mechanism involved. Other possible mechanisms, account-
ing particularly for long-term BP reduction, include nephron 
remodeling, reduction in arterial stiffness, and loss of body 
weight.29 The renin–angiotensin system (RAS) plays a major 
role in the regulation of BP and fluid volume. Although the 
systemic RAS is important, the locally acting RAS, particu-
larly that of the kidneys, is critical. There is a concern that 
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the sodium/volume loss induced by SGLT2is could activate 
the RAS, indeed Cherney et al30 have reported that total 
angiotensinogen excretion, a marker of local RAS activity in 
the kidney,31 significantly increases in type 1 diabetic patients 
(T1DM) treated with SGLT2is. A recent study, however, has 
shown that the total urinary angiotensinogen/creatinine ratio 
and intact angiotensinogen/creatinine ratio tended to decrease 
in T2DM patients treated with SGLT inhibitors.32
Several SGLT inhibitors have currently been approved 
in Europe and the USA (dapagliflozin, canagliflozin, and 
empagliflozin) while others are still under investigation 
(sotaglifozin and ertugliflozin). The main selectivity differ-
ences are summarized in Table 1.33–37
This review focuses on the efficacy and safety of the 
highly selective and reversible SGLT2i ertugliflozin.
Methods
A systematic literature search was conducted using elec-
tronic databases, including PubMed and Web of Science. 
Different keywords were used to identify key papers related 
to preclinical and human studies on ertugliflozin, including 
“ertugliflozin” or “PF-04971729” or “SGLT2 inhibitors” or 
“type 2 diabetes mellitus.”
We focused our selection, prioritizing randomized con-
trolled clinical trials with ertugliflozin and other SGLT2is. 
We also focused on meta-analyses and systematic reviews. 
Reference lists of the principal articles considered were 
used to find additional relevant papers. No restrictions were 
adopted for other study characteristics, such as numbers of 
subjects enrolled, endpoints, and so on.
Ertugliflozin: pharmacokinetics, 
metabolism, and excretion
Ertugliflozin (PF-04971729) is a novel molecule belong-
ing to a new class of SGLT2is incorporating a unique 
dioxa-bicyclo [3.2.1] octane (bridged ketal) ring system 
(Figure 1), which has demonstrated remarkable selectivity 
in vitro (2,000-fold) for SGLT2 receptors over SGLT1 
and revealed a concentration-dependent glycosuria after oral 
administration in rats.33
An open-label Phase I study showed that plasma con-
centration peaks ~1 hour after administration of a single oral 
dose of [14C]-Ertugliflozin 25 mg in healthy male subjects, 
indicating rapid oral absorption. Systemic exposure was 
dose proportional over the dose range of 0.5–300 mg, while 
elimination half-life was about 17 hours, making once-a-day 
dosing possible.38
Furthermore, ertugliflozin was found to be highly bound 
to plasma protein (96% in rats and dogs, 94% in humans) 
and binding was independent of concentration in the vari-
ous species.39
Its primary biotransformation pathway is glucuronidation, 
through UDP-glucuronosyltranferase isozyme IA9, which is 
involved in the formation of the two main ertugliflozin metab-
olites: ertugliflozin-4-β-O-glucuronide and ertugliflozin- 
3-β-O-glucuronide (M4a and M4c). The oxidative metabolic 
pathway plays a lesser role, through cytochrome P450 (P450), 
to yield monohydroxylated metabolites (M1 and M3) and 
des-ethyl ertugliflozin (M2). Renal excretion of unchanged 
ertugliflozin is considered negligible, whereas almost half of 
the orally administered dose is recovered as urinary metabo-
lites (Figure 2).40
Given the recent advent of fixed-dose combination drugs 
(FDCs), an ertugliflozin-sitagliptin FDC trial was conducted 
and has recently been completed. This open-label, random-
ized, three-period, single-dose, crossover study, in which 
12 healthy adult subjects received ertugliflozin 15 mg, sita-
gliptin 100 mg and ertugliflozin plus sitagliptin, showed that 
coadministration of ertugliflozin and sitagliptin had no effect 
on either ertugliflozin AUC
inf
 or C
max
; similarly, ertugliflozin 
did not affect sitagliptin AUC
inf
 or C
max
. Analogous results 
were obtained with metformin. The absence of pharma-
cokinetic interaction demonstrates that ertugliflozin can be 
coadministered with both sitagliptin and metformin without 
dose adjustments.41
Table 1 SGLT2/SGLT1 selectivity of main SGLT inhibitors33–37
Molecule SGLT2
(IC50 nM)
SGLT1
(IC50 nM)
SGLT2 selectivity 
over SGLT1
Empagliflozin 3.1 8,300 ~2,500-fold
Ertugliflozin 0.87 1,960 ~2,000-fold
Dapagliflozin 1.2 1,400 ~1,200-fold
Canagliflozin 2.7 710 ~250-fold
Sotagliflozin 1.8 36 ~20-fold
Phlorizin 2,800 4,200 ~1.5-fold
Abbreviations: iC50, half-maximal inhibitory concentration; SGLT, sodium-glucose 
cotransporter.
??
?
?
?
??
??
??
??
Figure 1 Molecular structure of ertugliflozin: (1S,2S,3S,4R,5S)-5-[4-Chloro-3- 
(4-ethoxybenzyl)phenyl]-1-hydroxymethyl6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol 
(PF-04971729).
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As renal impairment is a common comorbidity in T2DM, 
the effect of renal impairment on pharmacokinetics and 
pharmacodynamics has been evaluated in T2DM subjects. 
A single oral dose of ertugliflozin 15 mg was administered to 
normal subjects and to subjects with varying degrees of renal 
impairment. As expected, systemic exposure to ertugliflozin 
increased by 2-fold in subjects with renal impairment com-
pared to subjects with normal renal function, and 24-hour 
urinary glucose excretion decreased with declining renal 
function, due to decreased filtered glucose load. Ertugliflozin 
is therefore well tolerated in subjects with normal renal func-
tion and in T2DM subjects with renal impairment.42
Studies on ertugliflozin
The efficacy and safety of ertugliflozin, as monotherapy 
and as add-on/combination therapy with other antidiabetic 
drugs in patients with diabetes mellitus, is currently being 
established through a series of Phase II and Phase III trials, 
the VERTIS Studies: eValuation of ERTugliflozin effIcacy 
and Safety. To date, there are six completed Phase III studies, 
whose main characteristics are illustrated in Table 2.
Efficacy
Blood glucose control
In a Phase II study, ertugliflozin was evaluated at doses rang-
ing from 1 to 25 mg (1, 5, 10, 25 mg) once-daily, in patients 
with T2DM in treatment with stable doses of metformin, 
compared with sitagliptin 100 mg and placebo; mean HbA1c 
decreased from baseline to week 12 in all ertugliflozin groups 
(from −0.45% to −0.72% depending on the treatment group), 
compared with placebo. In particular, doses of more than 
5 mg/day yielded an effect on HbA1c that was numerically 
???????????????????
?????????
??
???
???
??
??
???????????????
??
?
?
?
??
??
??
??
?????????
??????????
??????????????????????
??
?
?
?
??
??
??
??
? ?
Figure 2 (A) Hepatic metabolism of ertugliflozin. Its primary biotransformation pathway is glucuronidation, through UDP-glucuronosyltranferase isozyme IA9, which is 
involved in the formation of the two main ertugliflozin metabolites: ertugliflozin-4-β-O-glucuronide and ertugliflozin-3-β-O-glucuronide (M4a and M4c). Oxidative metabolic 
pathway plays a lesser role, through cytochrome P450 (P450), to yield monohydroxylated metabolites (M1 and M3) and des-ethyl ertugliflozin (M2). (B) Excretion of 
unchanged ertugliflozin.
Table 2 Phase iii completed clinical trials
Study No of 
patients
Duration 
(weeks)
Background  
therapy
Arms
veRTiS MONO44,45 461 26+26 Diet and exercise eRTU 5 mg eRTU 15 mg Placebo (phase A)/
metformin (phase B)
veRTiS MeT46 621 26+26 Metformin  
1,500 mg die
eRTU 5 mg eRTU 15 mg Placebo
veRTiS 
FACTORiAL47,48
1,233 26+26 Metformin  
1,500 mg die
eRTU 5 mg eRTU 15 mg Sita 100 mg eRTU 5 mg + 
SiTA 100 mg
eRTU 15 mg + 
SiTA 100 mg
veRTiS SiTA49 291 26 Diet and exercise eRTU 5 mg + 
SiTA 100 mg
eRTU 15 mg + 
SiTA 100 mg
Placebo
veRTiS SiTA250,51 463 26+26 Metformin  
1,500 mg die +  
Sitagliptin 100 mg die
eRTU 5 mg eRTU 15 mg Placebo
veRTiS SU52 1,326 52 Metformin  
1,500 mg die
eRTU 5 mg eRTU 15 mg Titrated glimepiride
Abbreviations: ERTU, ertugliflozin; SITA, sitagliptin.
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similar to that obtained with sitagliptin 100 mg. A greater 
proportion of patients treated with ertugliflozin reached 
HbA1c 7% at week 12 and a significant reduction from base-
line in fasting plasma glucose (FPG) was also observed.43
The VERTIS MONO Phase III trial evaluated the effi-
cacy and safety of ertugliflozin monotherapy in subjects 
with T2DM and inadequate glycemic control, despite diet 
and exercise (Table 2). Results from the placebo-controlled 
phase (phase A) of this study have been published recently.44 
Change from baseline in HbA1c at week 26 showed a sig-
nificantly greater decrease in the ertugliflozin 5 mg (−0.99%; 
p0.001) and 15 mg (−1.16%; p0.001) groups, compared 
with placebo, which was more evident in subjects with base-
line HbA1c 8%. At week 26, ertugliflozin 5 and 15 mg also 
achieved a significantly greater reduction in the secondary 
endpoints, namely, FPG and 2-hour postprandial glucose, 
compared with placebo (Figure 3; Table S1).44
Data from the active, controlled 26-week follow-up phase 
were recently presented at the 77th ADA scientific session. 
Patients previously treated with placebo had metformin 
added, but there were no formal comparisons for efficacy 
between placebo/metformin group and ertugliflozin group 
at week 52. There was a meaningful reduction in HbA1c 
from baseline, in both ertugliflozin groups (Table S1), the 
same benefit was observed in FPG reduction (ertugliflozin 
5 mg −30.07 mg/dL; ertugliflozin 15 mg −37.55 mg/dL).45
Ertugliflozin efficacy has also been evaluated as add-on 
or combination therapy with sitagliptin and metformin. The 
VERTIS MET trial investigated the efficacy and safety 
of ertugliflozin, versus placebo, in patients with T2DM, 
inadequately controlled with metformin monotherapy 
(1,500 mg/day 8 weeks) (Table 2). At week 26, both the 
ertugliflozin groups showed a significant decrease in HbA1c 
and FPG from baseline. Specifically, ertugliflozin 5 mg, com-
pared with placebo, caused a reduction in HbA1c of −0.7% 
(p0.001) and of −26.69 mg/dL (p0.001) in FPG, while 
ertugliflozin 15 mg caused a reduction of −0.88% (p0.001) 
in HbA1c and of −38.25 mg/dL (p0.001) in FPG (Figure 3; 
Table S1).46
The VERTIS FACTORIAL study investigated the 
efficacy and safety of coadministration of ertugliflozin 5 or 
15 mg plus sitagliptin 100 mg compared with either treatment 
as monotherapy (Table 2). After 26 weeks, coadministra-
tion of ertugliflozin + sitagliptin was significantly more 
effective than either treatment alone in reducing HbA1c 
and FPG and increasing the number of patients achieving 
HbA1c 7.0%. Ertugliflozin 5 mg, ertugliflozin 15 mg, 
and sitagliptin 100 mg showed a reduction from baseline 
in HbA1c of −1.0%, −1.1%, and −1.1%, respectively (p is 
nonsignificant among the three groups); the addition of 
sitagliptin 100 mg determined a further decrease in HbA1c 
(ertugliflozin 5 mg + sitagliptin 100 mg −1.5%; ertugliflozin 
????????????????
?????
?????
?????
?????
?????
?????
?
?
?
?
? ?
? ?
? ?
?????????????
???
???
?????
???
????
?
??????????????????
??????????? ???????????? ???????????????? ???????????????????? ??????????
??? ???????
????????????????????
??????????????????????? ????????????????????????
??????????
Figure 3 Mean change in HbA1c.
Notes: *p0.001. ap0.004 versus individual treatment.
Abbreviations: ERTU, ertugliflozin; HbA1c, glycosylated hemoglobin; SITA, sitagliptin; PBO, placebo.
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15 mg + sitagliptin 100 mg −1.5%; p0.004) (Figure 3; 
Table S1).
Similar results were obtained for FPG in terms of reduction 
from baseline (ertugliflozin 5 mg −35.7 mg/dL; ertugliflozin 
15 mg −36.9 mg/dL; sitagliptin 100 mg −25.6 mg/dL; ertug-
liflozin 5 mg + sitagliptin 100 mg −44 mg/dL; ertugliflozin 
15 mg + sitagliptin 100 mg −48.7 mg/dL). Importantly, 
with sitagliptin 100 mg and ertugliflozin coadministration, 
a greater proportion of patients achieved HbA1c 7.0% 
(ertugliflozin 5 mg + sitagliptin 100 mg: 52.3%; ertugliflozin 
15 mg + sitagliptin 100 mg: 49.2%; ertugliflozin 5 mg: 
26.4%; ertugliflozin 15 mg: 31.9%; sitagliptin 100 mg: 
32.8%).47 The treatment was continued in a double-blind 
26-week extension phase, attaining an even greater decrease 
in HbA1c and FPG (Table S1).48
The VERTIS SITA trial investigated the efficacy of 
ertugliflozin in combination with sitagliptin in subjects 
with T2DM inadequately controlled with diet and exercise. 
Subjects were randomized 1:1:1 to take ertugliflozin 5 mg + 
sitagliptin 100 mg, ertugliflozin 15 mg + sitagliptin 100 mg 
or placebo (Table 2). As expected, after 26 weeks, the two 
treatment groups showed a larger reduction from baseline 
in HbA1c, which was significant in the pairwise comparison 
with placebo (ertugliflozin 5 mg + sitagliptin 100 mg −1.16%, 
p0.001; ertugliflozin 15 mg + sitagliptin 100 mg −1.24%, 
p0.001) (Figure 3, Table S1). There was also a mean-
ingful reduction in FPG (ertugliflozin 5 mg + sitagliptin 
100 mg: −48.3 mg/dL; ertugliflozin 15 mg + sitagliptin 
100 mg: −55.4 mg/dL; placebo: −9.3 mg/dL) and 2-hour 
post-meal glucose PMG (ertugliflozin 5 mg + sitagliptin 
100 mg: −82.8 mg/dL; ertugliflozin 15 mg + sitagliptin 
100 mg: −90 mg/dL; placebo: −20.4 mg/dL). Furthermore, 
the respective comparison with placebo, for both FPG and 
2-hour PMG, was significant (p0.001). The percentage of 
subjects achieving HbA1c 7.0% was higher with ertugli-
flozin + sitagliptin compared to placebo (ertugliflozin 5 mg + 
sitagliptin 100 mg: 35.7%; ertugliflozin 15 mg + sitagliptin 
100 mg: 31.3%; placebo: 8.3%).49
VERTIS SITA2, another study in the VERTIS clinical 
development program, assessed the safety and efficacy of 
adding ertugliflozin 5 or 15 mg compared with placebo to the 
dual combination of metformin and sitagliptin, after 26 weeks 
of treatment (Table 2). Blood glucose control after 26 weeks 
of treatment was more effective with ertugliflozin 5 and 
15 mg compared with placebo. In particular, the mean change 
in HbA1c was greater with ertugliflozin 5 mg (−0.68%, 
p0.001) and 15 mg (−0.76%, p0.001) compared with 
placebo (−0.1%). The same effects were observed for FPG 
(5 mg −26.9 mg/dL; 25 mg −33.1 mg/dL; PBO −1.8 mg/dL) 
and a greater proportion of subjects treated with ertugli-
flozin 5 and 25 mg reached the target of HbA1c 7.0.50 
The study extension at 52 weeks has shown similar results 
(Table S1).51
The VERTIS SU trial evaluated the efficacy and safety 
of once-daily ertugliflozin 15 or 5 mg compared with 
glimepiride (initiated at 1 mg and uptitrated to a maximum 
of 6 or 8 mg/day) over 52 weeks, in patients with T2DM 
inadequately controlled with metformin. The primary end-
point was to assess non-inferiority in reducing HbA1c. Ertug-
liflozin 15 mg was non-inferior to glimepiride in reducing 
HbA1c (ertugliflozin 15 mg vs glimepiride: 0.1 [−0.0; 0.2] 
p0.001) while non-inferiority could not be demonstrated 
for ertugliflozin 5 mg (0.2 [0.1; 0.3] p=ns).52
Body weight
As mentioned earlier, SGLT2 inhibition promotes significant 
energy loss through glycosuria, which causes weight loss.53 
This is evident within 4 weeks of treatment but continues 
for up to 102 weeks in the longer duration trials.54,55 In par-
ticular, reduction in body-fat mass accounts for 68%–90% of 
the weight loss induced by SGLT2is, as reported in several 
clinical trials.14,56–58
As with other gliflozins, ertugliflozin is also effective 
in reducing body weight, as proven in several randomized 
controlled trials, probably due to caloric loss and increased 
diuresis.14,59–61 After 12 weeks of ertugliflozin, at doses rang-
ing from 1 to 25 mg, body weight decreased significantly in 
all treatment groups, compared with placebo and sitagliptin 
100 mg.43
After 26 weeks of ertugliflozin monotherapy (5 and 
15 mg), T2DM subjects, inadequately controlled by diet and 
exercise alone, achieved significant weight loss compared to 
placebo (ertugliflozin 5 mg −1.76 kg, p0.001; ertugliflozin 
15 mg −2.16 kg, p0.001)44 (Figure 4). Weight loss contin-
ued till week 52, after the active-controlled second phase of 
the study: at this point, the ertugliflozin 5 mg group showed 
a 3.23 kg decrease in body weight and the ertugliflozin 
15 mg group a 3.38 kg decrease, compared with baseline 
values (Table S2).45
In the VERTIS MET trial, the addition of ertugliflozin 
5 and 15 mg to at least 1,500 mg of metformin determined 
significant weight loss, compared to placebo (Figure 4).46
Coadministration of ertugliflozin 5 and 15 mg and sita-
gliptin 100 mg led to an effective decrease in body weight 
(ertugliflozin 5 mg + sitagliptin 100 mg: −2.5 kg, p0.001; 
ertugliflozin 15 mg + sitagliptin 100 mg: −2.9 kg, p0.001), 
Drug Design, Development and Therapy 2017:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2911
Spotlight on ertugliflozin
compared to sitagliptin alone, which was not significant if 
compared to ertugliflozin 5 and 15 mg alone (sitagliptin 
100 mg: −0.7 kg; ertugliflozin 5 mg: −2.7 kg; ertugliflozin 
15 mg: −3.7 kg).47
A similar body weight reduction for each group was 
reached at week 52 (Table S2).48
The VERTIS SITA trial showed that ertugliflozin 5 mg 
or ertugliflozin 15 mg with sitagliptin combination therapy 
was effective in inducing weight loss, compared to placebo 
(ertugliflozin 5 mg + sitagliptin 100 mg: −2.0 kg, p0.001; 
ertugliflozin 15 mg + sitagliptin 100 mg: −3 kg, p0.001) 
after 26 weeks of treatment (Figure 4).49
Furthermore, the addition of ertugliflozin 5 or 15 mg 
to metformin 1,500 mg and sitagliptin 100 mg determined 
considerable body weight reduction, compared with placebo 
(ertugliflozin 5 mg: −2 kg, p0.001; ertugliflozin 15 mg: −1.7 kg, 
p0.001), which persisted at week 52 (Figure 4; Table S2).50,51
As expected, in the VERTIS SU trial, both ertugliflozin 
5 and 15 mg induced a greater weight loss compared to 
glimepiride (ertugliflozin 5 mg vs glimepiride: −3.9 kg 
[−4.4; −3.4] nominal p0.001; ertugliflozin 15 mg vs 
glimepiride: −4.3 kg [−4.8; −3.8] p0.001).52
Blood pressure
As previously explained, SGLT2is play an important role in low-
ering both SBP and DBP. A Phase II dose-ranging study showed 
a decrease in SBP from baseline (placebo-corrected least squares 
mean) as early as week 4 with ertugliflozin 5 mg (−2.59 mmHg; 
p=0.087) and 10 mg (−2.86 mmHg; p=0.068), which contin-
ued to be observed at week 12 with ertugliflozin 5–25 mg/day 
(5 mg: −3.48 mmHg, p=0.056; 10 mg: −2.88 mmHg, p=0.096; 
25 mg: −3.37 mmHg, p=0.064).43
In the first-phase VERTIS MONO trial, the ertugli-
flozin 15 mg versus placebo comparison for SBP was not 
significant, so the pre-specified hypothesis testing sequence 
was halted and testing of ertugliflozin 5 mg versus placebo 
for SBP and for both ertugliflozin groups versus placebo 
for DBP was not performed.44 At week 52, however, a 
meaningful reduction was observed in SBP (ertugliflozin 
5 mg: −3.27 mmHg; ertugliflozin 15 mg: −2.24 mmHg) rather 
than DBP (ertugliflozin 5 mg: −0.73 mmHg; ertugliflozin 
15 mg: 0.18 mmHg).45
However, results from other Phase III studies have shown 
significant reductions in SBP when ertugliflozin was added to 
metformin or metformin and sitagliptin (VERTIS FACTO-
RIAL, VERTIS SITA, and VERTIS SITA2); therefore, like 
other SGLT2is, ertugliflozin is effective in reducing BP.
In the VERTIS SU trial, both 5 and 15 mg ertugliflozin 
groups showed a greater reduction in SBP compared to 
glimepiride (ertugliflozin 5 mg vs glimepiride: −3.2 mmHg 
[−4.7; −1.7] nominal p0.001; ertugliflozin 15 mg vs 
glimepiride: −4.8 mmHg [−6.3; −3.3] nominal p0.001).52
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Figure 4 Mean change in body weight.
Notes: *p0.001. ap0.005 versus SiTA.
Abbreviations: ERTU, ertugliflozin; SITA, sitagliptin; PBO, placebo.
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Safety and tolerability
Adverse events
SGLT2is seem to obtain clinical benefits without significant 
side effects or are at least well tolerated.62 The most com-
monly reported side effects are genital fungal infections 
(GFIs) and rare urinary tract infections (UTIs) triggered by 
the glycosuria.63
In a Phase II dose-ranging study, in T2DM patients 
inadequately controlled with metformin, ertugliflozin was 
generally well tolerated over the 12-week treatment period.43 
Serious adverse events (cellulitis, syncope, and acute myo-
cardial infarction) have been recorded in pre-randomization 
and post-randomization phases of the study, even though 
none were considered treatment related. The most commonly 
reported adverse events (AEs) across all treatment groups 
were upper respiratory tract infections, diarrhea, UTIs, and 
GFIs. The latter two occurred in seven of the 328 subjects 
(two in placebo, two in ertugliflozin 1 mg, three in ertugli-
flozin 10 mg group) and nine of the 328 randomized patients 
(one in placebo, one in ertugliflozin 5 mg, three in ertugli-
flozin 10 mg, and four in ertugliflozin 25 mg). No subjects 
receiving sitagliptin had signs/symptoms of UTI or GFI. 
Ten participants experienced hypoglycemia AEs during 
the study; five during the metformin run-in period and five 
during the treatment period (three in ertugliflozin 5 mg; one 
in 10 mg; one in 25 mg). None of these required external 
assistance. General frequency of AEs symptomatic of volume 
depletion (eg, dehydration, hypotension, and hypovolemia) 
was rare; four subjects reported dizziness (possible volume 
depletion AE).
The ertugliflozin safety profile is therefore similar to that 
of other SGLT2is.64 In conclusion, ertugliflozin was well 
tolerated in this population, with the majority of AEs being 
of mild or moderate intensity.
In a Phase III study (VERTIS MONO), the total inci-
dence of AEs in ertugliflozin and placebo groups was similar 
(Table 3). Both the doses of ertugliflozin (5 and 15 mg) were 
generally safe and well tolerated during the study period 
(26 weeks). Genital mycotic infections in women occurred 
in 11 (16.4%) and 14 (22.6%) participants in the ertugliflozin 
5 and 15 mg groups, respectively, compared with four par-
ticipants (5.6%) in the placebo group (p=0.043 and p=0.005 
for ertugliflozin 5 and 15 mg, respectively, compared with 
placebo).
In men, genital mycotic infections occurred in three 
(3.4%) and five (5.6%) participants in the ertugliflozin 
5 and 15 mg groups, respectively, compared with 1 (1.2%) 
in the placebo group. There were no serious genital mycotic 
Table 3 Phase iii completed clinical trials: adverse events
Study Arms Adverse events
GFI
(women)
GFI
(men)
UTI Symptomatic 
hypoglycemia
Hypovolemia
veRTiS MONO44,45
(after 52 weeks)
PBO/MET (n=153) 7 (9.9) 1 (1.2) 21 (13.7) 7 (4.6) 7 (4.6)
ERTU 5 mg (n=156) 18 (26.9)a 3 (3.4) 17 (10.9) 2 (1.3) 3 (1.9)
ERTU 15 mg (n=152) 18 (29)b 7 (7.8)c 10 (6.6)d 4 (2.6) 3 (2.0)
veRTiS MeT46 PBO (n=209) 1 (0.9) 0 (0.0) 2 (1.0) 4 (1.9) 1 (0.5)
ERTU 5 mg (n=207) 6 (5.5) 3 (3.1) 6 (2.9) 7 (3.4) 1 (0.5)
ERTU 15 mg (n=205) 7 (6.3)e 3 (3.2) 7 (3.4) 7 (3.4) 2 (1.0)
veRTiS  
FACTORiAL47,48,*
ERTU 5 mg (n=250) – – – 2.4 1.6
ERTU 15 mg (n=248) – – – – 0.8
SITA 100 mg (n=247) – – – – 0
eRTU 5 mg + SITA 100 mg (n=243) – – – – 0
eRTU 15 mg + SITA 100 mg (n=244) – – – 4.9 0
veRTiS SiTA49,** PBO (n=97) 2 (5.0) 0 (0.0) 5 (5.2) 1 (1.0) 1 (1.0)
eRTU 5 mg + SITA 100 mg (n=98) 2 (4.9) 3 (5.3) 8 (8.2) 3 (3.1) 2 (2.0)
eRTU 15 mg + SITA 100 mg (n=96) 3 (7.0) 1 (1.9) 3 (3.1) 3 (3.1) 2 (2.1)
veRTiS SiTA250,51
(after 26 weeks)
PBO (n=153) 1.9 0 2 2.6 0.7
ERTU 5 mg (n=156) 8 4.9 2.6 3.2 0.6
ERTU 15 mg (n=153) 12.7 3.7 4.6 0.7 0
veRTiS SU52 ERTU 5 mg (n=448) 17 (7.7) 10 (4.4) 30 (6.7) 14 (3.1) 5 (1.3)
ERTU 15 mg (n=440) 25 (10.0) 4 (2.1) 28 (6.4) 23 (5.2) 3 (0.7)
Titrated glimepiride (n=437) 3 (1.4) 0 (0) 30 (6.9) 84 (19.2) 3 (0.7)
Notes: ap=0.010 vs PBO/MeT; bp=0.005 vs PBO/MeT; cp=0.042 vs PBO/MeT; dp=0.039 PBO/MeT; eincidence significantly higher (p=0.032) versus PBO. *Empty cells = incomplete 
data and/or see text. **All p-values for the comparison between eRTU 5/SiTA 100 vs PBO and eRTU 15/ SiTA 100 vs PBO are 0.05.
Abbreviations: ERTU, ertugliflozin; SITA, sitagliptin; MET, metformin; PBO, placebo; GFI, genital fungal infection; UTI, urinary tract infection.
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infection AEs. In general, genital mycotic infections in 
women had a significantly higher incidence with ertugliflozin 
than in the placebo group. The incidence of genital mycotic 
infections was also higher in men in the ertugliflozin groups 
compared with placebo groups, but this difference was not 
significant.
The incidence of UTI in the ertugliflozin 5 and 15 mg 
groups was 7.1% and 3.9%, respectively, compared with 
8.5% for placebo. One UTI AE led to discontinuation of 
the study medication in a man in the placebo group. There 
were no serious UTI AEs. The incidence of hypovolemia in 
the ertugliflozin 5 and 15 mg groups was 1.3% and 2.0%, 
respectively, compared with 3.9% in the placebo group.
Events associated with symptomatic hypoglycemia and 
documented hypoglycemia were unusual in both the ertug-
liflozin and placebo groups. The percentage of participants 
with symptomatic hypoglycemia AEs were placebo, 1.3%; 
ertugliflozin 5 mg, 1.3%; and ertugliflozin 15 mg, 2.6%. 
Documented hypoglycemia, which included symptomatic 
and asymptomatic hypoglycemia, occurred in one participant 
(0.7%) in the placebo group and four participants (2.6%) in 
each of the ertugliflozin 5 and 15 mg groups. Two participants 
in the ertugliflozin 15 mg group experienced a severe hypogly-
cemia AE; one episode required non-professional assistance 
and one required professional assistance (Table 3).44
An increased incidence of genital mycotic infections was 
reported in the Phase III VERTIS MET study. Adverse events 
in women increased in the ertugliflozin 5 mg group and were 
markedly higher in the ertugliflozin 15 mg group compared 
to placebo (p=0.032). The incidence in men was higher in 
both ertugliflozin groups versus placebo. The incidence of 
UTIs and symptomatic hypoglycemia AEs was greater in 
both ertugliflozin groups versus placebo. The incidence of 
hypovolemia was low and similar across all treatment groups. 
In conclusion, ertugliflozin was largely well tolerated but 
was correlated with a higher incidence of genital mycotic 
infections compared with placebo (Table 3).46
In the VERTIS FACTORIAL double-blind Phase III 
trial, the incidence of adverse events was identical across 
groups, except for higher rates of genital mycotic infec-
tions in groups treated with ertugliflozin vs sitagliptin alone 
(females, 4.9%–7.6% vs 1.1%; males, 2.4%–4.7% vs 0%, 
respectively).
UTI rates were higher with ertugliflozin alone (but not 
ertugliflozin + sitagliptin) vs sitagliptin alone (range: 3.2% 
[SITA] to 5.6% [ERTU 15 mg]). The incidence of symptom-
atic hypoglycemia was 2.4%, in the group treated with ertug-
liflozin 5 mg and 4.9% in the group treated with ertugliflozin 
15 mg + sitagliptin. Hypovolemia AE rates were 1.6% and 
0.8% in ertugliflozin 5 and 15 mg groups, respectively, and 
0% in all other groups (Table 3).47
After 52 weeks, the percentage of genital mycotic infec-
tions in the treatment groups with ertugliflozin + sitagliptin 
was similar to that observed in the treatment group with 
ertugliflozin alone and significantly higher than that observed 
in the group treated with sitagliptin alone (p0.05, except 
ertugliflozin 5 mg + sitagliptin in females).
Incidence of symptomatic hypoglycemia did not dif-
fer across groups but was higher in the group treated with 
ertugliflozin 15 mg + sitagliptin. Incidence of UTIs and 
hypovolemia was comparable across groups.48
In the Phase III VERTIS SITA trial, the incidence of AEs 
was not meaningfully different across groups (all p-values 
for the comparison between Ertu 5/Sita 100 vs placebo and 
Ertu 15/Sita 100 versus placebo are 0.05); no deaths were 
recorded during the study (Table 3).49
In the VERTIS SITA2 Phase III trial, after 26 weeks, the 
incidence of AEs was comparable among treatment groups, 
but a higher rate of genital mycotic infections was recorded 
with ertugliflozin 5 and 15 mg (males: 4.9% and 3.7% vs 
no events with placebo; females: 8.0% and 12.7% vs 1.9% 
with placebo).
Incidence of UTI was similar in placebo and ertugliflozin 
5 mg groups (2.0% and 2.6%) but higher in the ertugliflozin 
15 mg group (4.6%).
Among groups, rates were similar for symptomatic 
hypoglycemia (placebo 2.6%; ertugliflozin 5 mg, 3.2%; 
ertugliflozin 15 mg, 0.7%) and hypovolemia AEs (placebo 
0.7%; ertugliflozin 5 mg, 0.6%; ertugliflozin 15 mg, no 
events) (Table 3).50
After 52 weeks, rates of genital mycotic infections were 
higher in ertugliflozin treatment groups compared to placebo 
(males: ertugliflozin 5 mg 4.9%, ertugliflozin 15 mg 3.7%, 
placebo 0%; females: ertugliflozin 5 mg 12.0%, ertugliflozin 
15 mg 14.1%, placebo 1.9%; all p0.05 vs placebo except 
ertugliflozin 15 mg males). The incidence of UTIs, symp-
tomatic hypoglycemia and hypovolemia AEs did not differ 
significantly among groups.51
In the VERTIS SU trial, after 52 weeks, compared to 
glimepiride, the ertugliflozin 5 and 15 mg treatment groups 
showed higher rates of genital mycotic infections (males: 
ertugliflozin 5 mg 10 [4.4], ertugliflozin 15 mg 4 [82.1], 
glimepiride 0 [0]), while no significant difference in UTIs 
and hypovolemia were observed among the three groups 
(Table 3). As expected, both ertugliflozin groups showed 
less symptomatic hypoglycemia than the glimepiride group 
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(ertugliflozin 5 mg 14 [3.1]; ertugliflozin 15 mg 23 [5.2]; 
glimepiride 84 [19.2]).52
Laboratory variables
To date, few data have been collected on changes in low-
density lipoprotein – high-density lipoprotein (LDL-HDL) 
cholesterol during treatment with SGLT2s. Previous studies 
observed a slight increment in LDL and HDL cholesterol, 
even though the mechanism remains unknown.3,64
In the VERTIS MONO Phase III study, mean baseline 
LDL cholesterol was ~100 mg/dL in all treatment groups. 
At week 26, the LS mean placebo-adjusted percent change 
in LDL cholesterol from baseline was 4.05% (95% CI −2.82, 
10.92) and 8.69% (95% CI 1.75, 15.63) for ertugliflozin 5 and 
15 mg, respectively. Mean baseline HDL cholesterol level 
was ~45 mg/dL for each treatment group. At week 26, the LS 
mean placebo-adjusted percent change in HDL cholesterol 
from baseline was 4.70% (95% CI 0.71, 8.69) and 8.57% 
(95% CI 4.55, 12.59) for ertugliflozin 5 and 15 mg groups, 
respectively.44
In the Phase III VERTIS MET study, at week 26, in both 
treatment groups with ertugliflozin 5 mg or 15 mg, eGFR 
values were similar at baseline (mean [SD] change from base-
line, mL/min/1.73 m2: placebo 1.0 [10.7], ertugliflozin 5 mg 0.3 
[12.0], ertugliflozin 15 mg 0.2 [14.8]). The placebo adjusted 
difference in LS mean (95% CI) percent change from baseline 
to week 26 in LDL-C was 2.0 (−6.0, 10.0) for ertugliflozin 5 mg 
and 2.6 (−5.5, 10.7) for ertugliflozin 15 mg. Respective values 
for HDL-C were 4.5 (1.4, 7.6) and 4.4 (1.3, 7.5).46
Conclusion
Ertugliflozin represents another valid SGLT2i for the treat-
ment of T2DM. As with other gliflozins, its insulin-indepen-
dent mechanism is effective in reducing HbA1c, BP, and body 
weight, both as monotherapy and in combination with other 
glucose-lowering agents. Individual variations in response to 
SGLT2is have been reported, partially attributable to genetic 
variations.65 T2DM is a heterogeneous disease, and response 
to an antidiabetic medication, such as an SGLT2i, could vary 
considerably among individuals; therefore, identification of 
pharmacogenetic biomarkers to predict therapeutic response 
might be important to maximize benefits and minimize side 
effects in personalized medicine.66
As expected, the clinical benefits of ertugliflozin are 
obtained without significant side effects. Currently, clinical 
trials investigating the safety and efficacy of ertugliflozin in 
treating T1DM are still lacking. Despite the thrilling results 
obtained in SGLT2i clinical trials, in terms of not only 
glycemic control but also CV protection, one conundrum still 
awaits solution: will gliflozins change the natural history of 
diabetes? To date, not surprisingly, sequential add-on therapy 
results with ertugliflozin have shown a significant improve-
ment in glucose metabolism. We still lack data from studies on 
head to head comparison of SGLT2i molecules, which might 
help to choose the right medication case by case. However, the 
possibility of having ertugliflozin in combination therapy with 
sitagliptin, the most prescribed DPP-4 inhibitor, is an undeni-
able advantage. In future, one challenge might be to study their 
effects as combined initial therapy in newly diagnosed T2DM, 
having durability as a primary outcome, that is, the ability to 
maintain adequate glucose control without the (usual) need to 
add further treatment. Gliflozins, in combination with a DPP-4 
inhibitor and metformin, as initial therapy, could modify the 
natural history of diabetes and slow down its progression.67
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